BioCentury | Mar 31, 2021
Emerging Company Profile

Entrada: Moving cell-penetrating DMD therapy into clinic with $116M series B

...Doshi called an IND-ready dataset for ENTR-501, an enzyme replacement therapy that delivers a conjugated TYMP...
...CureDuchenne VenturesCEO: Dipal DoshiPatents: Nine granted patents covering compositions of matter, manufacturing and useTARGETSTYMPThymidine phosphorylase Paul...
BioCentury | Jul 8, 2019
Clinical News

July 8 Clinical Quick Takes: Hemophilia data from Sangamo-Pfizer, Novo; plus GamaMabs, Xarelto and more

...Tokyo:4578) and Servier (Neuilly-sur-Seine, France) market Lonsurf, a combination of nucleoside analog trifluridine (FTD) and thymidine phosphorylase...
BioCentury | Mar 1, 2019
Clinical News

FDA approves Lonsurf for gastric cancer

...of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase...
BioCentury | May 18, 2018
Clinical News

Taiho's Lonsurf meets OS endpoint in Phase III for gastric cancer

...of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase...
...of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase...
...life (QOL) and safety Status: Phase III data Milestone: NA Sandi Wong Lonsurf, trifluridine/tipiracil (TAS-102) Servier Taiho Pharmaceutical Co. Ltd. Thymidine phosphorylase (TYMP)...
BioCentury | Feb 28, 2018
Distillery Techniques

Disease models

...combination of the nucleoside analog trifluridine (FTD) and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase...
BioCentury | Dec 7, 2016
Company News

Lonsurf sales and marketing update

...of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase...
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Thymidine phosphorylase (TYMP)

...Cancer INDICATION: Musculoskeletal Patient sample and mouse studies suggest inhibiting TYMP could help treat bone loss...
...treat bone loss in multiple myeloma (MM). In patient primary tumor and bone marrow samples, TYMP...
...include testing TYMP inhibition in animal models of bone loss related to other cancers. TARGET/MARKER/PATHWAY: Thymidine phosphorylase (TYMP)...
BioCentury | Sep 5, 2016
Company News

Servier, Taiho sales and marketing update

...of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase...
BioCentury | Aug 1, 2016
Company News

Servier, Taiho sales and marketing update

...of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase...
BioCentury | Jul 22, 2016
Company News

NICE recommends Lonsurf

...of trifluridine (FTD), an antineoplastic nucleoside analog; and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase...
Items per page:
1 - 10 of 31